Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

SPRB 10.28.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-11
Name of Upcoming Event:Guggenheim Securities Healthcare Innovation Conference
Full Press ReleaseSEC FilingsOur SPRB Tweets

About Gravity Analytica

Recent News

  • 12.10.2024 - Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
  • 11.11.2024 - Guggenheim Securities Healthcare Innovation Conference
  • 11.11.2024 - Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Recent Filings

  • 01.10.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 12.27.2024 - 8-K Current report
  • 12.20.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 28, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced thatJavier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at theGuggenheim Securities Healthcare Innovation ConferenceonNovember 11, 2024, at3:30 p.m. ET.

Interested parties can access the live webcasthere.An archived copy of the webcast will be available on theeventssection of the company’sinvestor relations websitefor approximately 90 days.

AboutSpruce Biosciences

Spruce Biosciencesis a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF1receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visitwww.sprucebio.comand follow us onX,LinkedIn,FacebookandYouTube.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241028643351/en/

MediaKatie Beach OltsikInizio Evoke Comms(937) 232-4889Katherine.Beach@inizioevoke.commedia@sprucebio.comInvestorsSamir GharibPresident and CFOSpruce Biosciences, Inc.investors@sprucebio.com

Source:Spruce Biosciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com